<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(8)</volume><submitter>Nguyen NT</submitter><pubmed_abstract>Despite evidence of SGLT2 inhibitors in improving cardiovascular outcomes of heart failure with preserved ejection fraction (HFpEF), the heterogenous mechanism and characteristic multimorbidity of HFpEF require a phenotypic approach. Metabolic phenotype, one common HFpEF phenotype, has various presentations and prognoses worldwide. We aimed to identify different phenotypes of hypertensive-diabetic HFpEF, their phenotype-related outcomes, and treatment responses. The primary endpoint was time to the first event of all-cause mortality or hospitalization for heart failure (HHF). Among 233 recruited patients, 24.9% experienced primary outcomes within 12 months. A total of 3.9% was lost to follow-up. Three phenotypes were identified. Phenotype 1 (n = 126) consisted of lean, elderly females with</pubmed_abstract><journal>Journal of personalized medicine</journal><pagination>1218</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10455077</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Phenotype-Specific Outcome and Treatment Response in Heart Failure with Preserved Ejection Fraction with Comorbid Hypertension and Diabetes: A 12-Month Multicentered Prospective Cohort Study.</pubmed_title><pmcid>PMC10455077</pmcid><pubmed_authors>Nguyen HH</pubmed_authors><pubmed_authors>Truong BQ</pubmed_authors><pubmed_authors>Nguyen NT</pubmed_authors><pubmed_authors>Nguyen HA</pubmed_authors><pubmed_authors>Chau HN</pubmed_authors></additional><is_claimable>false</is_claimable><name>Phenotype-Specific Outcome and Treatment Response in Heart Failure with Preserved Ejection Fraction with Comorbid Hypertension and Diabetes: A 12-Month Multicentered Prospective Cohort Study.</name><description>Despite evidence of SGLT2 inhibitors in improving cardiovascular outcomes of heart failure with preserved ejection fraction (HFpEF), the heterogenous mechanism and characteristic multimorbidity of HFpEF require a phenotypic approach. Metabolic phenotype, one common HFpEF phenotype, has various presentations and prognoses worldwide. We aimed to identify different phenotypes of hypertensive-diabetic HFpEF, their phenotype-related outcomes, and treatment responses. The primary endpoint was time to the first event of all-cause mortality or hospitalization for heart failure (HHF). Among 233 recruited patients, 24.9% experienced primary outcomes within 12 months. A total of 3.9% was lost to follow-up. Three phenotypes were identified. Phenotype 1 (n = 126) consisted of lean, elderly females with</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jul</publication><modification>2026-06-23T03:13:34.045Z</modification><creation>2025-04-07T10:22:20.049Z</creation></dates><accession>S-EPMC10455077</accession><cross_references><pubmed>37623468</pubmed><doi>10.3390/jpm13081218</doi></cross_references></HashMap>